Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 4/2024

12.02.2024 | Peripheral Vascular Disease (S Kinlay, Section Editor)

Open Surgical Therapy for Peripheral Artery Disease

verfasst von: Emmanuel C. Nwachuku, Alik Farber

Erschienen in: Current Cardiology Reports | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The surgical management of symptomatic peripheral artery disease (PAD) has changed in the last few decades. Improvement in endovascular technology has resulted in more complex lesion once reserved for open surgery being addressed in an endovascular fashion. Even with these advances, there are lesions and patients that are better managed with an open surgical procedure. The aim of this review is to describe the most commonly performed open surgical procedures for PAD.

Recent Findings

The recently published Best Endovascular versus Best Surgical Therapy (BEST-CLI) trial was an international, prospective, randomized controlled trial that aimed to investigate which revascularization (endovascular vs. surgical bypass) approach was superior for limb salvage. The evidence supports an open surgical bypass as an initial approach.

Summary

The advancements made in the surgical management of PAD have provided options for patients who were once deemed poor surgical candidates. The goal continues to be utilization of the best available tools to address patient disease. In this current era, it is important to be familiar with the open surgical therapies.
Literatur
1.
Mustapha JA, Katzen BT, Neville RF, Lookstein RA, Zeller T, Miller LE, et al. Determinants of long-term outcomes and costs in the management of critical limb ischemia: a population-based cohort study. J Am Heart Assoc. 2018;7(16): e009724.CrossRefPubMedPubMedCentral
2.
Scully RE, Arnaoutakis DJ, DeBord SA, Semel M, Nguyen LL. Estimated annual health care expenditures in individuals with peripheral arterial disease. J Vasc Surg. 2018;67(2):558–67.CrossRefPubMed
3.
Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation. 2021;144(9):e171–91.CrossRefPubMedPubMedCentral
4.
Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020–30.CrossRefPubMed
5.
Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110(6):738–43.CrossRefPubMed
6.
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007 Jan;45 Suppl S:S5–67.
7.
Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015 Mar;61(3 Suppl):2S-41S.
8.
Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62(6):1642-1651.e3.CrossRefPubMed
9.
Farber A, Eberhardt RT. The current state of critical limb ischemia: a systematic review. JAMA Surg. 2016;151(11):1070–7.CrossRefPubMed
10.
Kim ES, Sharma AM, Scissons R, Dawson D, Eberhardt RT, Gerhard-Herman M, et al. Interpretation of peripheral arterial and venous Doppler waveforms: a consensus statement from the Society for Vascular Medicine and Society for Vascular Ultrasound. Vasc Med. 2020;25(5):484–506.CrossRefPubMed
11.
Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000 Jan;31(1 Pt 2):S1–296.
12.
Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019 Jul;58(1S):S1-S109.e33.
13.
14.
Inahara T. Evaluation of endarterectomy for aortoiliac and aortoiliofemoral occlusive disease. Arch Surg. 1975;110(12):1458–64.CrossRefPubMed
15.
Kang JL, Patel VI, Conrad MF, Lamuraglia GM, Chung TK, Cambria RP. Common femoral artery occlusive disease: contemporary results following surgical endarterectomy. J Vasc Surg. 2008;48(4):872–7.CrossRefPubMed
16.
Sidawy AN, Perler BA. Aortoiliac disease: direct reconstruction. In: Rutherford’s Vascular surgery and endovascular therapy. 10th Edition. Philadelphia: Elsevier; 2023.
17.
Rollins DL, Towne JB, Bernhard VM, Baum PL. Endarterectomized superficial femoral artery as an arterial patch. Arch Surg. 1985;120(3):367–9.CrossRefPubMed
18.
Soden PA, Zettervall SL, Shean KE, Deery SE, Kalish JA, Healey CT, et al. Effect of adjunct femoral endarterectomy in lower extremity bypass on perioperative and 1-year outcomes. J Vasc Surg. 2017;65(3):711-719.e1.CrossRefPubMed
19.
Malgor RD, Ricotta JJ, Bower TC, Oderich GS, Kalra M, Duncan AA, et al. Common femoral artery endarterectomy for lower-extremity ischemia: evaluating the need for additional distal limb revascularization. Ann Vasc Surg. 2012;26(7):946–56.CrossRefPubMed
20.
Siracuse JJ, Gill HL, Schneider DB, Graham AR, Connolly PH, Jones DW, et al. Assessing the perioperative safety of common femoral endarterectomy in the endovascular era. Vasc Endovascular Surg. 2014;48(1):27–33.CrossRefPubMed
21.
Stricker H, Jacomella V. Stent-assisted angioplasty at the level of the common femoral artery bifurcation: midterm outcomes. J Endovasc Ther. 2004;11(3):281–6.CrossRefPubMed
22.
Siracuse JJ, Van Orden K, Kalish JA, Eslami MH, Schermerhorn ML, Patel VI, et al. Endovascular treatment of the common femoral artery in the Vascular Quality Initiative. J Vasc Surg. 2017;65(4):1039–46.CrossRefPubMed
23.
de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. J Vasc Surg. 1997;26(4):558–69.CrossRefPubMed
24.
Chiesa R, Marone EM, Tshomba Y, Logaldo D, Castellano R, Melissano G. Aortobifemoral bypass grafting using expanded polytetrafluoroethylene stretch grafts in patients with occlusive atherosclerotic disease. Ann Vasc Surg. 2009;23(6):764–9.CrossRefPubMed
25.
DeCarlo C, Boitano LT, Schwartz SI, Lancaster RT, Conrad MF, Eagleton MJ, et al. Laparotomy- and groin-associated complications are common after aortofemoral bypass and contribute to reintervention. J Vasc Surg. 2020;72(6):1976–86.CrossRefPubMed
26.
Sharma G, Scully RE, Shah SK, Madenci AL, Arnaoutakis DJ, Menard MT, et al. Thirty-year trends in aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. 2018;68(6):1796-1804.e2.CrossRefPubMed
27.
Abdelkarim AH, Dakour-Aridi H, Gurakar M, Nejim B, Locham S, Malas MB. Association between statin use and perioperative mortality after aortobifemoral bypass in patients with aortoiliac occlusive disease. J Vasc Surg. 2019;70(2):509–15.CrossRefPubMed
28.
Mwipatayi BP, Thomas S, Wong J, Temple SEL, Vijayan V, Jackson M, et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011;54(6):1561–70.CrossRefPubMed
29.
Dorigo W, Piffaretti G, Benedetto F, Tarallo A, Castelli P, Spinelli F, et al. A comparison between aortobifemoral bypass and aortoiliac kissing stents in patients with complex aortoiliac obstructive disease. J Vasc Surg. 2017;65(1):99–107.CrossRefPubMed
30.
Chaikof EL, Cambria RP, editors. Extraanatomic repair of aortoiliac occlusive disease. In: Atlas of vascular surgery and endovascular therapy: anatomy and technique. Philadelphia, PA: Elsevier Saunders; 2014.
31.
Taylor LM, Park TC, Edwards JM, Yeager RA, McConnell DC, Moneta GA, et al. Acute disruption of polytetrafluoroethylene grafts adjacent to axillary anastomoses: a complication of axillofemoral grafting. J Vasc Surg. 1994 Oct;20(4):520–6; discussion 526–528.
32.
Passman MA, Taylor LM, Moneta GL, Edwards JM, Yeager RA, McConnell DB, et al. Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. 1996 Feb;23(2):263–9; discussion 269–271.
33.
Harrington ME, Harrington EB, Haimov M, Schanzer H, Jacobson JH. Axillofemoral bypass: compromised bypass for compromised patients. J Vasc Surg. 1994;20(2):195–201.CrossRefPubMed
34.
Schneider JR, McDaniel MD, Walsh DB, Zwolak RM, Cronenwett JL. Axillofemoral bypass: outcome and hemodynamic results in high-risk patients. J Vasc Surg. 1992 Jun;15(6):952–62; discussion 962–963.
35.
Martin D, Katz SG. Axillofemoral bypass for aortoiliac occlusive disease. Am J Surg. 2000;180(2):100–3.CrossRefPubMed
36.
Taylor LM, Moneta GL, McConnell D, Yeager RA, Edwards JM, Porter JM. Axillofemoral grafting with externally supported polytetrafluoroethylene. Arch Surg. 1994 Jun;129(6):588–94; discussion 594–595.
37.
Samson RH, Showalter DP, Lepore MR, Nair DG, Dorsay DA, Morales RE. Improved patency after axillofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. 2018;68(5):1430–7.CrossRefPubMed
38.
Levin SR, Farber A, King EG, Beck AW, Osborne NH, DeMartino RR, et al. Outcomes of axillofemoral bypass for intermittent claudication. J Vasc Surg. 2022;75(5):1687-1694.e4.CrossRefPubMed
39.
Johnson WC, Lee KK. Comparative evaluation of externally supported Dacron and polytetrafluoroethylene prosthetic bypasses for femorofemoral and axillofemoral arterial reconstructions. Veterans Affairs Cooperative Study #141. J Vasc Surg. 1999 Dec;30(6):1077–83.
40.
Flanigan DP, Pratt DG, Goodreau JJ, Burnham SJ, Yao JS, Bergan JJ. Hemodynamic and angiographic guidelines in selection of patients for femorofemoral bypass. Arch Surg. 1978;113(11):1257–62.CrossRefPubMed
41.
Aburahma AF, Robinson PA, Cook CC, Hopkins ES. Selecting patients for combined femorofemoral bypass grafting and iliac balloon angioplasty and stenting for bilateral iliac disease. J Vasc Surg. 2001;33(2 Suppl):S93-99.CrossRefPubMed
42.
Ricco JB, Probst H, French University Surgeons Association. Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease. J Vasc Surg. 2008 Jan;47(1):45–53; discussion 53–54.
43.
Schneider JR, Besso SR, Walsh DB, Zwolak RM, Cronenwett JL. Femorofemoral versus aortobifemoral bypass: outcome and hemodynamic results. J Vasc Surg. 1994 Jan;19(1):43–55; discussion 55–57.
44.
Plecha FR, Plecha FM. Femorofemoral bypass grafts: ten-year experience. J Vasc Surg. 1984;1(4):555–61.CrossRefPubMed
45.
Hinchliffe RJ, Alric P, Wenham PW, Hopkinson BR. Durability of femorofemoral bypass grafting after aortouniiliac endovascular aneurysm repair. J Vasc Surg. 2003;38(3):498–503.CrossRefPubMed
46.
Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986;3(1):104–14.CrossRefPubMed
47.
Pomposelli FB, Jepsen SJ, Gibbons GW, Campbell DR, Freeman DV, Miller A, et al. Efficacy of the dorsal pedal bypass for limb salvage in diabetic patients: short-term observations. J Vasc Surg. 1990 Jun;11(6):745–51; discussion 751–752.
48.
Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006 Apr;43(4):742–51; discussion 751.
49.
Byrne J, Darling RC, Chang BB, Paty PS, Kreienberg PB, Lloyd WE, et al. Infrainguinal arterial reconstruction for claudication: is it worth the risk? An analysis of 409 procedures. J Vasc Surg. 1999 Feb;29(2):259–67; discussion 267–269.
50.
Kobayashi M, Hida K, Shikata H, Sakamoto S, Matsubara J. Long term outcome of femoropopliteal bypass for claudication and critical ischemia. Asian Cardiovasc Thorac Ann. 2004;12(3):208–12.CrossRefPubMed
51.
Cull DL, Langan EM, Gray BH, Johnson B, Taylor SM. Open versus endovascular intervention for critical limb ischemia: a population-based study. J Am Coll Surg. 2010 May;210(5):555–61, 561–3.
52.
Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366(9501):1925–34.CrossRefPubMed
53.
• Bradbury AW, Moakes CA, Popplewell M, Meecham L, Bate GR, Kelly L, et al. A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet. 2023 May 27;401(10390):1798–809. In this trial, patients with CLTI who needed an infra-popliteal revascularization with or without a more proximal procedure had a better amputation-free survival when they were treated with an endovascular approach as opposed to open surgical bypass. This finding was largely due to fewer deaths in the endovascular group.
54.
•• Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med. 2022 Dec 22;387(25):2305–16. Results from this trial showed that patients with CLTI who had adequate great saphenous vein and underwent open surgical bypass had a lower incidence of major adverse limb event or death when compared to patients in the endovascular group. This result was driven by fewer major reinterventions and above-ankle amputations in the surgical group.
55.
Menard MT, Sharma G, Belkin M. Aortoiliac disease: direct reconstruction (Chapter 109). In Rutherford’s vascular surgery and endovascular therapy, 2-voume set, 10th edition. Edited by Sidawy AN, Perler BA. Elsevier; Amsterdam, The Netherlands: 2023:1434–1451.e3.
56.
Schneider J. Aortoiliac disease: open extra-anatomic bypass (chapter 110). In Rutherford’s vascular surgery and endovascular therapy, 2-voume set, 10th edition. Edited by Sidawy AN, Perler BA. Elsevier; Amsterdam, The Netherlands: 2023: 1452–1459.e2.
Metadaten
Titel
Open Surgical Therapy for Peripheral Artery Disease
verfasst von
Emmanuel C. Nwachuku
Alik Farber
Publikationsdatum
12.02.2024
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 4/2024
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02027-4

Weitere Artikel der Ausgabe 4/2024

Current Cardiology Reports 4/2024 Zur Ausgabe

Myocardial Disease (A Abbate and M Merlo, Section Editors)

Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention

Management of Acute Coronary Syndromes (H Jneid, Section Editor)

Updates on Non-Statin LDL-Lowering Therapy

Ischemic Heart Disease (D Mukherjee, Section Editor)

Update on the Role of Colchicine in Cardiovascular Disease

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

The Global Epidemic of Metabolic Fatty Liver Disease

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen